JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Scope & Guideline

Illuminating the path to ocular health advancements.

Introduction

Explore the comprehensive scope of JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1080-7683
PublisherMARY ANN LIEBERT, INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1985 to 2024
AbbreviationJ OCUL PHARMACOL TH / J. Ocular Pharmacol. Ther.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801

Aims and Scopes

The Journal of Ocular Pharmacology and Therapeutics focuses on advancing the field of ocular pharmacology through innovative research and clinical studies. It encompasses a wide range of topics that combine pharmacological approaches with therapeutic interventions for various ocular diseases.
  1. Ocular Drug Development and Delivery Systems:
    The journal emphasizes novel drug delivery systems and formulations designed to enhance the efficacy and safety of ocular therapeutics. This includes research on nanotechnology, polymeric micelles, and sustained-release systems.
  2. Pharmacological Therapies for Ocular Diseases:
    A core focus is on pharmacological treatments for conditions such as glaucoma, dry eye disease, and retinal disorders. This involves both systemic and topical therapies, as well as the evaluation of new pharmacological agents.
  3. Mechanisms of Disease and Pathophysiology:
    Research articles often explore the underlying mechanisms of ocular diseases, including neurodegeneration, inflammation, and fibrosis. Understanding these mechanisms is crucial for developing targeted therapies.
  4. Clinical Trials and Efficacy Studies:
    The journal publishes findings from clinical trials that assess the safety and efficacy of new treatments in human subjects, providing valuable insights into real-world applications of ocular therapeutics.
  5. Innovative Therapeutic Modalities:
    The journal includes studies on gene therapy, stem cell therapy, and other cutting-edge approaches aimed at regenerating ocular tissues and restoring vision.
The Journal of Ocular Pharmacology and Therapeutics is witnessing several emerging trends that reflect the evolving landscape of ocular research and therapy.
  1. Nanotechnology and Advanced Drug Delivery:
    There is a growing trend towards exploring nanotechnology and advanced drug delivery mechanisms, with studies focusing on how these innovations can improve therapeutic outcomes in ocular diseases.
  2. Biologics and Targeted Therapies:
    Research on biologics, including monoclonal antibodies and gene therapies, is increasing. These therapies offer targeted approaches to treat complex ocular conditions, such as age-related macular degeneration and diabetic retinopathy.
  3. Regenerative Medicine:
    An emerging focus on regenerative medicine techniques, including stem cell therapy and tissue engineering, is evident. This reflects a broader interest in restoring function and repairing damaged ocular tissues.
  4. Personalized Medicine Approaches:
    The journal is increasingly publishing studies that emphasize personalized medicine, tailoring treatments based on individual patient characteristics and disease profiles.
  5. Ocular Safety and Toxicology Studies:
    There is a notable increase in research dedicated to evaluating the safety and toxicological profiles of new ocular therapies, addressing concerns about long-term effects and patient safety.

Declining or Waning

While the Journal of Ocular Pharmacology and Therapeutics continues to thrive in many areas, some themes appear to be declining in prominence based on recent publications.
  1. Traditional Pharmacological Agents:
    There is a noticeable decrease in studies focusing solely on traditional pharmacological agents, such as older classes of eye drops and systemic medications, as the field shifts towards more innovative therapies.
  2. Invasive Surgical Techniques:
    Research on invasive surgical techniques for treating ocular diseases is diminishing in frequency. The trend is moving towards less invasive options and pharmacological alternatives.
  3. General Reviews without Novel Insights:
    The prevalence of general review articles that do not provide novel insights or data is declining, as the journal increasingly prioritizes original research that contributes new knowledge to the field.

Similar Journals

International Journal of Pharmacology

Empowering Scholars to Shape the Future of Pharmacology
Publisher: ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINETISSN: 1811-7775Frequency: 8 issues/year

Welcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.

ANTI-CANCER DRUGS

Empowering Researchers in the Fight Against Cancer
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Augenheilkunde Up2date

Exploring the Frontiers of Vision Science.
Publisher: GEORG THIEME VERLAG KGISSN: 1616-9719Frequency: 4 issues/year

Augenheilkunde Up2date is a pivotal journal in the field of ophthalmology, published by GEORG THIEME VERLAG KG, a renowned publisher known for its commitment to advancing medical knowledge. With its ISSN 1616-9719 and E-ISSN 1616-9735, this journal serves as a vital resource for researchers, professionals, and students interested in the latest developments and nuanced discussions in eye health. Although not available as open access, its curated content offers significant insights into contemporary research, clinical practices, and emerging trends in ophthalmology, thus promoting the continuous professional development of its readers. There is an emphasis on providing comprehensive reviews that encapsulate the pertinent advancements in the field, making it an essential publication for those aiming to enhance their expertise in eye care and vision science.

CORNEA

Pioneering insights into corneal diseases and treatments.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0277-3740Frequency: 12 issues/year

CORNEA is a prestigious peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the rapidly advancing field of ophthalmology with a particular emphasis on corneal research and diseases. With an impact factor categorized in the prestigious Q1 quartile for its discipline, CORNEA has established itself as a leading platform for the dissemination of both fundamental and clinical studies since its inception in 1982. The journal is ranked 25th out of 137 in the Scopus Medicine-Ophthalmology category, placing it in the 82nd percentile among its peers, which underscores its vital role in influencing ocular research and clinical practices. While the journal is not currently open access, it provides valuable insights and updates for professionals, researchers, and students working to advance knowledge in corneal health, contributing significantly to the ongoing dialogue in the ophthalmological community. With a commitment to excellence, CORNEA continues to publish high-quality research and reviews in its pursuit to improve ocular outcomes and patient care.

PROGRESS IN RETINAL AND EYE RESEARCH

Pioneering Discoveries in Ophthalmology
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 1350-9462Frequency: 6 issues/year

PROGRESS IN RETINAL AND EYE RESEARCH, published by PERGAMON-ELSEVIER SCIENCE LTD, is a premier journal dedicated to the advancement of knowledge in the fields of ophthalmology and sensory systems. With an impressive impact factor and a Q1 category ranking in both Ophthalmology and Sensory Systems as of 2023, this journal exemplifies excellence in research dissemination. Given its stature, it ranks #1 out of 137 in Ophthalmology and #1 out of 42 in Neuroscience - Sensory Systems, placing it within the top percentile of scientific publications in these domains. The journal has been actively contributing to the field since its inception in 1994 and continues to be a vital resource for researchers, clinicians, and students seeking the latest insights and breakthroughs in the understanding of retinal diseases and eye health. While it maintains a traditional subscription model, the journal remains committed to publishing high-quality, peer-reviewed articles that drive forward the frontiers of eye research and therapeutic innovation. With its strong scientific rigor and a vast array of articles, PROGRESS IN RETINAL AND EYE RESEARCH is indispensable for anyone invested in the study of visual sciences.

Biologics-Targets & Therapy

Empowering Research in Gastroenterology and Beyond
Publisher: DOVE MEDICAL PRESS LTDISSN: 1177-5475Frequency: 1 issue/year

Biologics-Targets & Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, specializing in the fields of Gastroenterology, Immunology and Allergy, Oncology, Pharmacology (Medical), and Rheumatology. Launched in 2007, the journal has established a solid reputation for disseminating high-quality research that bridges the gap between laboratory findings and clinical application, offering insights into the therapeutic potential of biologics. With a commendable impact factor and placement in Q1 quartiles across multiple medical domains in 2023, Biologics-Targets & Therapy ranks among the top journals in its categories, providing a platform for researchers and clinicians to share their latest discoveries. Researchers can access articles freely, promoting wider dissemination and collaboration in the scientific community. By publishing innovative studies and reviews, this journal plays a pivotal role in advancing the understanding and therapeutic applications of biologics, making it an essential resource for professionals and students alike.

Translational Vision Science & Technology

Exploring New Horizons in Eye Health and Technology
Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INCISSN: 2164-2591Frequency: 6 issues/year

Translational Vision Science & Technology is a premier open access journal dedicated to the advancement of the field of ophthalmology and biomedical engineering. Published by the Association for Research in Vision and Ophthalmology, Inc., this journal has established itself as a leading source of high-quality research since its inception in 2013, achieving a remarkable impact factor reflective of its influential contribution to the field. With an impressive ranking of #21 in Ophthalmology and #120 in Biomedical Engineering within the Scopus database, it sits within the prestigious Q1 quartile for both categories as of 2023, further validating its significance. The journal's scope encompasses a wide variety of topics focused on the intersection of ophthalmological science and technological innovation, welcoming contributions that promote the understanding and treatment of visual disorders. Available as an Open Access publication since 2016, it ensures that cutting-edge research is freely accessible to researchers, practitioners, and students worldwide, facilitating the rapid dissemination of knowledge essential for the advancement of vision science.

EXPERIMENTAL EYE RESEARCH

Pioneering Insights into Eye Function and Disorders
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 0014-4835Frequency: 12 issues/year

EXPERIMENTAL EYE RESEARCH, published by Academic Press Ltd - Elsevier Science Ltd, is a preeminent journal dedicated to advancing the fields of ophthalmology and neuroscience. With a history of insightful publications dating back to 1961, this journal serves as a critical platform for researchers, professionals, and students interested in the cellular and molecular mechanisms underlying visual processes. The journal boasts impressive rankings, including being placed in the top quartile (Q1) of both the Ophthalmology and Sensory Systems categories, and is recognized in the 2nd quartile (Q2) for Cellular and Molecular Neuroscience. With an impact factor reflecting its significant contribution to the field, EXPERIMENTAL EYE RESEARCH is a valuable resource that promotes the exchange of innovative research and ideas essential for understanding the complexities of eye function and vision-related disorders. Researchers looking to publish their findings or stay abreast of the latest studies will find this journal a vital component of their academic toolkit.

Journal of Ophthalmic & Vision Research

Empowering Research in Ophthalmology
Publisher: KNOWLEDGE EISSN: 2008-2010Frequency: 4 issues/year

The Journal of Ophthalmic & Vision Research, published by KNOWLEDGE E, stands as a crucial platform for disseminating high-quality research in the field of ophthalmology. With an ISSN of 2008-2010 and an E-ISSN of 2008-322X, this journal fosters open access to valuable insights since 2010, enhancing visibility and reach for researchers globally. Based in Dubai, UAE, it has established a reputation for excellence, reflected in its Q2 ranking in Ophthalmology for 2023 and its position among the top 65th percentile in Scopus. Covering a broad spectrum of topics within ophthalmic science, the journal serves as a vital resource for professionals, researchers, and students by presenting original research, reviews, and case studies that drive innovation and collaboration within the community. As the journal continues to contribute to advancements in eye care and vision sciences, it invites scholars to explore, engage, and publish within its pages, thus enriching the global discourse on ophthalmic health.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Enhancing lives with cutting-edge cardiovascular pharmacological insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0160-2446Frequency: 12 issues/year

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.